NCT07045987

Brief Summary

The goal of this prospective cohort registration study is to establish an early warning system for futile recanalization in acute ischemic stroke by analyzing multi-omics information to identify key regulatory nodes and target molecules in ineffective recanalization. The core issue addressed by this research is: Identifying key regulatory nodes and target molecules closely associated with futile recanalization, revealing the interactions among the neurovascular unit, peripheral immune cells, and the brain lymphatic system, as well as developing early diagnostic biomarkers and novel diagnostic technologies for futile recanalization.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
38mo left

Started Jun 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress23%
Jun 2025May 2029

Study Start

First participant enrolled

June 1, 2025

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

June 23, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 1, 2025

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2029

Last Updated

July 1, 2025

Status Verified

March 1, 2025

Enrollment Period

3 years

First QC Date

June 23, 2025

Last Update Submit

June 23, 2025

Conditions

Acute Ischemic Stroke (AIS)Endovascular ThrombectomyNeurovascular Unit- Brain Lymphatic System

Outcome Measures

Primary Outcomes (1)

  • 3-month mRS score

    From enrollment to the end of treatment at 3 months

Other Outcomes (1)

  • All-cause mortality within 3 months

    From enrollment to the end of treatment at 3months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults (\>18y) with thrombectomy-eligible acute ischemic stroke confirmed by neuroimaging, meeting prespecified inclusion/exclusion criteria

You may qualify if:

  • \. Aged ≥18 years 2. Acute ischemic stroke confirmed by clinical and neuroimaging criteria (CT or MRI) 3. Clinical indication for thrombectomy 4. Provision of signed informed consent

You may not qualify if:

  • \. Preexisting dementia or severe disability (modified Rankin Scale score ≥3) 2. Cerebral vascular malformations, neoplasms, abscesses, or other significant non-ischemic brain pathologies 3. Life-limiting systemic comorbidities (e.g., end-stage organ failure, metastatic malignancies) with anticipated survival \<6 months 4. Patient or legally authorized representative declined consent 5. Anticipated poor protocol adherence or loss to follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Luojun WANG

Xi’an, Shanxi, 710077, China

Location

Related Publications (4)

  • Hussein HM, Georgiadis AL, Vazquez G, Miley JT, Memon MZ, Mohammad YM, Christoforidis GA, Tariq N, Qureshi AI. Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study. AJNR Am J Neuroradiol. 2010 Mar;31(3):454-8. doi: 10.3174/ajnr.A2006. Epub 2010 Jan 14.

    PMID: 20075087BACKGROUND

  • Liu X, Dai Q, Ye R, Zi W, Liu Y, Wang H, Zhu W, Ma M, Yin Q, Li M, Fan X, Sun W, Han Y, Lv Q, Liu R, Yang D, Shi Z, Zheng D, Deng X, Wan Y, Wang Z, Geng Y, Chen X, Zhou Z, Liao G, Jin P, Liu Y, Liu X, Zhang M, Zhou F, Shi H, Zhang Y, Guo F, Yin C, Niu G, Zhang M, Cai X, Zhu Q, Chen Z, Liang Y, Li B, Lin M, Wang W, Xu H, Fu X, Liu W, Tian X, Gong Z, Shi H, Wang C, Lv P, Tao Z, Zhu L, Yang S, Hu W, Jiang P, Liebeskind DS, Pereira VM, Leung T, Yan B, Davis S, Xu G, Nogueira RG; BEST Trial Investigators. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol. 2020 Feb;19(2):115-122. doi: 10.1016/S1474-4422(19)30395-3. Epub 2019 Dec 9.

    PMID: 31831388BACKGROUND

  • Ma H, Che R, Zhang Q, Yu W, Wu L, Zhao W, Li M, Wu D, Wu C, Ji X. The optimum anticoagulation time after endovascular thrombectomy for atrial fibrillation-related large vessel occlusion stroke: a real-world study. J Neurol. 2023 Apr;270(4):2084-2095. doi: 10.1007/s00415-022-11515-y. Epub 2023 Jan 3.

    PMID: 36596867BACKGROUND

  • Dong Q, Dong Y, Liu L, Xu A, Zhang Y, Zheng H, Wang Y. The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke. Stroke Vasc Neurol. 2017 Jun 2;2(3):147-159. doi: 10.1136/svn-2017-000074. eCollection 2017 Sep.

    PMID: 28989804BACKGROUND

Related Links

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 23, 2025

First Posted

July 1, 2025

Study Start

June 1, 2025

Primary Completion (Estimated)

May 31, 2028

Study Completion (Estimated)

May 31, 2029

Last Updated

July 1, 2025

Record last verified: 2025-03

Locations

CN(1)